Search research articles
Contact Us
Filters
Showing results (71-80 of 95) with videos related to
Page
of 10
Sort By:
Cancer
|
March 25, 2026
Final clinical data of a phase 1 dose-escalation study of WVT078, a BCMA×CD3 bispecific antibody, alone and in combination with γ-secretase inhibitor WHG626 in patients with relapsed and/or refractory multiple myeloma
Fredrik Schjesvold, Andrew Spencer, Yael C Cohen, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
November 29, 2021
Comparison of Cilta-cel, an Anti-BCMA CAR-T Cell Therapy, Versus Conventional Treatment in Patients With Relapsed/Refractory Multiple Myeloma
Luciano J Costa, Yi Lin, R Frank Cornell, et al.
Blood
|
July 9, 2020
Expression of NrasQ61R and MYC transgene in germinal center B cells induces a highly malignant multiple myeloma in mice
Zhi Wen, Adhithi Rajagopalan, Evan D Flietner, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
January 18, 2023
Systemic Light Chain Amyloidosis, Version 2.2023, NCCN Clinical Practice Guidelines in Oncology
Shaji K Kumar, Natalie S Callander, Kehinde Adekola, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
December 7, 2020
Multiple Myeloma, Version 3.2021, NCCN Clinical Practice Guidelines in Oncology
Shaji K Kumar, Natalie S Callander, Kehinde Adekola, et al.
Ejhaem
|
December 5, 2022
Selinexor-based regimens in patients with multiple myeloma after prior anti-B-cell maturation antigen treatment
Muhamed Baljevic, Cristina Gasparetto, Gary J Schiller, et al.
Blood
|
June 22, 2011
Trends in allogeneic stem cell transplantation for multiple myeloma: a CIBMTR analysis
Shaji Kumar, Mei-Jie Zhang, Peigang Li, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
January 6, 2022
NCCN Guidelines® Insights: Multiple Myeloma, Version 3.2022
Natalie S Callander, Muhamed Baljevic, Kehinde Adekola, et al.
British Journal of Cancer
|
November 21, 2021
Once weekly selinexor, carfilzomib and dexamethasone in carfilzomib non-refractory multiple myeloma patients
Cristina Gasparetto, Gary J Schiller, Sascha A Tuchman, et al.
Leukemia
|
March 13, 2019
Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy
Ujjawal H Gandhi, Robert F Cornell, Arjun Lakshman, et al.
Page
of 10
Search research articles
Search
Showing results (71-80 of 95) with videos related to
Sort By:
Page
of 10
Cancer
|
March 25, 2026
Final clinical data of a phase 1 dose-escalation study of WVT078, a BCMA×CD3 bispecific antibody, alone and in combination with γ-secretase inhibitor WHG626 in patients with relapsed and/or refractory multiple myeloma
Fredrik Schjesvold, Andrew Spencer, Yael C Cohen, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
November 29, 2021
Comparison of Cilta-cel, an Anti-BCMA CAR-T Cell Therapy, Versus Conventional Treatment in Patients With Relapsed/Refractory Multiple Myeloma
Luciano J Costa, Yi Lin, R Frank Cornell, et al.
Blood
|
July 9, 2020
Expression of NrasQ61R and MYC transgene in germinal center B cells induces a highly malignant multiple myeloma in mice
Zhi Wen, Adhithi Rajagopalan, Evan D Flietner, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
January 18, 2023
Systemic Light Chain Amyloidosis, Version 2.2023, NCCN Clinical Practice Guidelines in Oncology
Shaji K Kumar, Natalie S Callander, Kehinde Adekola, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
December 7, 2020
Multiple Myeloma, Version 3.2021, NCCN Clinical Practice Guidelines in Oncology
Shaji K Kumar, Natalie S Callander, Kehinde Adekola, et al.
Ejhaem
|
December 5, 2022
Selinexor-based regimens in patients with multiple myeloma after prior anti-B-cell maturation antigen treatment
Muhamed Baljevic, Cristina Gasparetto, Gary J Schiller, et al.
Blood
|
June 22, 2011
Trends in allogeneic stem cell transplantation for multiple myeloma: a CIBMTR analysis
Shaji Kumar, Mei-Jie Zhang, Peigang Li, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
January 6, 2022
NCCN Guidelines® Insights: Multiple Myeloma, Version 3.2022
Natalie S Callander, Muhamed Baljevic, Kehinde Adekola, et al.
British Journal of Cancer
|
November 21, 2021
Once weekly selinexor, carfilzomib and dexamethasone in carfilzomib non-refractory multiple myeloma patients
Cristina Gasparetto, Gary J Schiller, Sascha A Tuchman, et al.
Leukemia
|
March 13, 2019
Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy
Ujjawal H Gandhi, Robert F Cornell, Arjun Lakshman, et al.
Page
of 10